drugset / Trial / NCT02841709

Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder

NCT02841709

Phase 2 Completed 58 enrolled Idorsia Pharmaceuticals Ltd.
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study evaluates the dose response of ACT-541468 on the change of wake after sleep onset (WASO) assessed by polysomnography (PSG) on the first 2 days of each treatment period.

Timeline

Start
2016-11-28
Primary completion
2017-05-31
Completion
2017-06-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Daridorexant Small molecule 5 mg Oral
Subject Daridorexant Small molecule 10 mg Oral
Subject Daridorexant Small molecule 25 mg Oral
Subject Daridorexant Small molecule 50 mg Oral

Indications